Clinical Trial Update: Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases [Phase 1, Phase 2]

View source ↗

Summary

This document outlines an ongoing Phase 1/Phase 2 clinical trial evaluating total body irradiation in combination with an Astatine-211-labeled BC8-B10 monoclona…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Neoplasm

Drugs mentioned

• Astatine-211-labeled BC8-B10 monoclonal antibody (BC8-B10 monoclonal antibody labeled with Astatine-211)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Non-Malignant Neoplasm | Phase 1, Phase 2 | Status: RECRUITING